HIM
PTCT icon

Hillsdale Investment Management’s PTC Therapeutics PTCT Stock Holding History

Hillsdale Investment Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-75,706
Closed -$5.75M – 751
2025
Q4 		$5.75M Sell
75,706
-15,430
-17% -$1.12M 0.16% 173
2025
Q3 		$5.59M Sell
91,136
-16,620
-15% -$866K 0.17% 180
2025
Q2 		$5.26M Buy
107,756
+39,700
+58% +$1.88M 0.19% 157
2025
Q1 		$3.47M Buy
68,056
+67,886
+39,933% +$3.39M 0.18% 154
2024
Q4 		$7.67K Hold
170
– – ﹤0.01% 509
2024
Q3 		$6.31K Hold
170
– – ﹤0.01% 562
2024
Q2 		$5.2K Buy
+170
New +$5.51K ﹤0.01% 559
2023
Q3 		– Sell
-37,237
Closed -$1.51M – 635
2023
Q2 		$1.51M Sell
37,237
-13,400
-26% -$656K 0.14% 180
2023
Q1 		$2.45M Sell
50,637
-47,700
-49% -$2.18M 0.21% 145
2022
Q4 		$3.75M Sell
98,337
-2,000
-2% -$83.1K 0.32% 119
2022
Q3 		$5.04M Buy
+100,337
New +$4.92M 0.46% 70
2018
Q3 		– Sell
-2,300
Closed -$78K – 534
2018
Q2 		$78K Buy
+2,300
New +$71.7K 0.01% 300

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Hillsdale Investment Management's PTCT Position: Q1 2026 in Review

Hillsdale Investment Management sold out of PTC Therapeutics (PTCT) in Q1 2026, closing a stake of 75,706 shares — an estimated $5.75M sold.

Hillsdale Investment Management first reported a position in PTCT in Q2 2018 and held it in 12 quarters. The position peaked at $5.75M in Q4 2025. 352 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • Hillsdale Investment Management reported no remaining PTC Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Hillsdale Investment Management sold 75,706 PTC Therapeutics shares in Q1 2026, an estimated $5.75M.
  • Hillsdale Investment Management first reported a position in PTC Therapeutics in Q2 2018 and held it in 12 quarters.
  • Hillsdale Investment Management's PTC Therapeutics position peaked at $5.75M in Q4 2025.
  • 352 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Hillsdale Investment Management's 13F filing for Q1 2026, filed 4 May 2026.